Document Type
Preprint
Publication Date
11-15-2021
Journal / Book Title
ACS Medicinal Chemistry Letters
Abstract
The discovery of new targets for the treatment of malaria, in particular those aimed at the pre-erythrocytic stage in the life cycle, advanced with the demonstration that orally administered inhibitors of Plasmodium falciparum cGMP-dependent protein kinase (PfPKG) could clear infection in a murine model. This enthusiasm was tempered by unsatisfactory safety and/or pharmacokinetic issues found with these chemotypes. To address the urgent need for new scaffolds, this paper presents initial structure–activity relationships in an imidazole scaffold at four positions, representative in vitro ADME, hERG characterization, and cell-based antiparasitic activity. This series of PfPKG inhibitors has good in vitro PfPKG potency, low hERG activity, and cell-based antiparasitic activity against multiple Plasmodium species that appears to be correlated with the in vitro potency.
DOI
10.1021/acsmedchemlett.1c00540
Montclair State University Digital Commons Citation
Yadav Bheemanaboina, Rammohan R.; de Souza, Mariana Laureano; Gonzalez, Mariana Lozano; Mahmood, Shams ul; Eck, Tyler; Kreiss, Tamara; Aylor, Samantha O.; Roth, Alison; Lee, Patricia; Pybus, Brandon S.; Colussi, Dennis J.; Childers, Wayne E.; Gordon, John; Siekierka, John J.; Bhanot, Purnima; and Rotella, David P., "Discovery of Imidazole-Based Inhibitors of Plasmodium falciparum cGMP-Dependent Protein Kinase" (2021). Department of Chemistry and Biochemistry Faculty Scholarship and Creative Works. 656.
https://digitalcommons.montclair.edu/chem-biochem-facpubs/656
Published Citation
Bheemanaboina, Rammohan R. Yadav, et al. “Discovery of Imidazole-Based Inhibitors of Plasmodium Falciparum cGMP-Dependent Protein Kinase.” ACS Medicinal Chemistry Letters, vol. 12, no. 12, Dec. 2021, pp. 1962–67. https://doi.org/10.1021/acsmedchemlett.1c00540.